GSK Stock Recent News
GSK LATEST HEADLINES
PHILADELPHIA--(BUSINESS WIRE)-- #Adolescents--GSK's 5-in-1 meningococcal vaccine PENMENVY receives positive recommendation from US Advisory Committee on Immunization Practices.
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
The Company spend billions to produce 100% of its key medicines for Americans in the U.S.
The Trump administration's proposed tariffs on pharmaceuticals have caused significant market turmoil today, with major Pharma stocks plummeting globally. Despite pledges to increase U.S. manufacturing, companies like Eli Lilly and Novo Nordisk are suffering substantial share price declines. The feasibility of relocating drug manufacturing to the U.S. is highly questionable, potentially leading to drug shortages and higher domestic prices.
NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc ("GSK" or "the Company") (NYSE:GSK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired GSK American Depositary Receipts ("ADRs") between February 5, 2020 and August 14, 2022, both dates inclusive (the "Class Period").
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=141594&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against GSK plc (“GSK” or “the Company”) (NYSE: GSK) and certain of its officers.
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=141573&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=141540&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/gsk-lawsuit-submission-form?prid=141513&wire=1 or contact Joseph E. Levi, Esq.